WX [WuXi PharmaTech (Cayman)] 20-F: (Original Filing)

[WuXi PharmaTech (Cayman) Inc. Page INTRODUCTION 1 2 PART I. ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS 3 ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE 3 ITEM 3. KEY INFORMATION 3 ITEM 4. INFORMATION ON THE COMPANY 27 ITEM 4A. UNRESOLVED STAFF COMMENTS 49 ITEM 5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS 49 ITEM 6. DIRECTORS, SENIOR MANAGEMENT] [Execution Version Dated 16 February 2015 WUXI PHARMATECH (CAYMAN) INC. AS BORROWER WUXI APPTEC HOLDING COMPANY, INC. WUXI APPTEC, INC. WUXI APPTEC (BVI) INC. WUXI APPTEC (HONG KONG) LIMITED AS ORIGINAL GUARANTORS CITIGROUP GLOBAL MARKETS ASIA LIMITED AS COORDINATING ARRANGER AND CITICORP INTERNATIONAL LIMITED AS AGENT FACILITY AGREEMENT FOR US$165,000,000 SENIOR TERM AND REVOLVING LOAN FACILITY CONTENTS Clause Page 1.] [LIST OF SUBSIDIARIES Name Abbreviation Place of Incorporation WuXi AppTec (BVI) Inc. WXAT BVI British Virgin Islands WuXi AppTec Co., Ltd. WXAT PRC WuXi AppTec (Shanghai) Co., Ltd. WASH PRC Shanghai SynTheAll Pharmaceutical Co., Ltd. STA PRC WuXi AppTec (Suzhou) Co., Ltd. WASZ PRC WuXi AppTec (Tianjin) Co., Ltd. WATJ PRC WuXi AppTec Holding Company, Inc. AppTec Holding WuXi AppTec,] [Certification by the Chief Executive Officer I, Ge Li, certify that: 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered] [Certification by the Chief Financial Officer I, Edward Hu, certify that: 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered] [Section 906 of the Sarbanes-Oxley Act of 2002 Ge Li Chief Executive Officer EX-13.1 6 d796029dex131.htm EX-13.1] [Certification by the Chief Financial Officer Edward Hu Chief Financial Officer EX-13.2 7 d796029dex132.htm EX-13.2] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in this Registration Statement No. 333-182917 on Form S-8 of our reports dated April 15, 2015, relating to the consolidated financial statements and financial statement schedule of Wuxi PharmaTech (Cayman) Inc. and its subsidiaries, and the effectiveness of Wuxi PharmaTech (Cayman) Inc. and its subsidiaries’ internal]

By | 2016-03-24T02:47:01+00:00 April 15th, 2015|Categories: Chinese Stocks, SEC Original, WX|Tags: , , , , , |0 Comments

WX [WuXi PharmaTech (Cayman)] 20-F: WuXi PharmaTech (Cayman) Inc. Page INTRODUCTION 1 2

[WuXi PharmaTech (Cayman) Inc. Page INTRODUCTION 1 2 PART I. ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS 3 ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE 3 ITEM 3. KEY INFORMATION 3 ITEM 4. INFORMATION ON THE COMPANY 27 ITEM 4A. UNRESOLVED STAFF COMMENTS 49 ITEM 5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS 49 ITEM 6. DIRECTORS, SENIOR MANAGEMENT] [Execution Version Dated 16 February 2015 WUXI PHARMATECH (CAYMAN) INC. AS BORROWER WUXI APPTEC HOLDING COMPANY, INC. WUXI APPTEC, INC. WUXI APPTEC (BVI) INC. WUXI APPTEC (HONG KONG) LIMITED AS ORIGINAL GUARANTORS CITIGROUP GLOBAL MARKETS ASIA LIMITED AS COORDINATING ARRANGER AND CITICORP INTERNATIONAL LIMITED AS AGENT FACILITY AGREEMENT FOR US$165,000,000 SENIOR TERM AND REVOLVING LOAN FACILITY CONTENTS Clause Page 1.] [LIST OF SUBSIDIARIES Name Abbreviation Place of Incorporation WuXi AppTec (BVI) Inc. WXAT BVI British Virgin Islands WuXi AppTec Co., Ltd. WXAT PRC WuXi AppTec (Shanghai) Co., Ltd. WASH PRC Shanghai SynTheAll Pharmaceutical Co., Ltd. STA PRC WuXi AppTec (Suzhou) Co., Ltd. WASZ PRC WuXi AppTec (Tianjin) Co., Ltd. WATJ PRC WuXi AppTec Holding Company, Inc. AppTec Holding WuXi AppTec,] [Certification by the Chief Executive Officer I, Ge Li, certify that: 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered] [Certification by the Chief Financial Officer I, Edward Hu, certify that: 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered] [Section 906 of the Sarbanes-Oxley Act of 2002 Ge Li Chief Executive Officer EX-13.1 6 d796029dex131.htm EX-13.1] [Certification by the Chief Financial Officer Edward Hu Chief Financial Officer EX-13.2 7 d796029dex132.htm EX-13.2] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in this Registration Statement No. 333-182917 on Form S-8 of our reports dated April 15, 2015, relating to the consolidated financial statements and financial statement schedule of Wuxi PharmaTech (Cayman) Inc. and its subsidiaries, and the effectiveness of Wuxi PharmaTech (Cayman) Inc. and its subsidiaries’ internal]

By | 2016-03-24T02:48:18+00:00 April 15th, 2015|Categories: Chinese Stocks, Webplus ver, WX|Tags: , , , , , |0 Comments

SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 8-K: (Original Filing)

[SKYSTAR BIO-PHARMACEUTICAL COMPANY ANNOUNCES RECEIPT OF NASDAQ NON-COMPLIANCE LETTER DUE TO DELAY IN FILING FORM 10-K Xi’an, China, April 15, 2015 – Skystar Bio-Pharmaceutical Company (Nasdaq: SKBI), a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, announced today that the Company received a notification from the Nasdaq Stock Market (“Nasdaq”) informing the Company that since it] [805 King Farm Blvd. Rockville, MD 20850 / USA Nasdaq.com By Electronic Delivery to: bing@skystarbio-pharmaceutical.com; aorudjev@schiffhardin.com; scramer@skystarbio-pharmaceutical.com April 15, 2015 Mr. Bing Mei Chief Financial Officer Skystar Bio-Pharmaceutical Company 4/F Building B, Chuangye Square, No. 48 Keji Road Gaoxin District, Xi’an Shaanxi Province, P.R. China Re: Skystar Bio-Pharmaceutical Company (the “Company”) Nasdaq Symbol: SKBI Dear Mr. Mei: 1 I am] []

By | 2016-03-27T15:23:59+00:00 April 15th, 2015|Categories: Chinese Stocks, SEC Original, SKBI|Tags: , , , , , |0 Comments

CYD [CHINA YUCHAI INTERNATIONAL] 20-F: (Original Filing)

[CHINA YUCHAI INTERNATIONAL LIMITED Page Certain Definitions and Supplemental Information 2 2 Part I Item 1. Identity of Directors, Senior Management and Advisers 4 Item 2. Offer Statistics and Expected Timetable 4 Item 3. Key Information 4 Item 4. Information on the Company 22 Item 4A. Unresolved Staff Comments 38 Item 5. Operating and Financial Review and Prospects 38 Item] [The particulars of the Company’s subsidiaries as at December 31, 2014 are set forth below: Attributable equity interests Name of company Jurisdiction Direct Indirect Guangxi Yuchai Machinery Company Limited People’s Republic of — 76.4 % Guangxi Yuchai Accessories Manufacturing Company Limited PRC — 76.4 % Guangxi Yulin Yuchai Accessories Manufacturing Company Limited PRC — 74.2 % Guangxi Yuchai Machinery Monopoly] [TO SECTION 302 OF THE SARBANES-OXLEY ACT I, Hoh Weng Ming, certify that: 1. I have reviewed this annual report on Form 20-F of China Yuchai International Limited (the “Company”); 2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements] [TO SECTION 906 OF THE SARBANES-OXLEY ACT (ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. TO SECTION 906 OF THE SARBANES-OXLEY ACT (ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.] [Consent of Independent Registered Public Accountant Firm We consent to the incorporation by reference in the Registration Statement (Form S-8 No. 333-197287) pertaining to the Equity Incentive Plan of China Yuchai International Limited of our reports dated April 15, 2015, with respect to the consolidated financial statements of China Yuchai International Limited and the effectiveness of internal control over financial]

By | 2016-03-28T12:29:40+00:00 April 15th, 2015|Categories: Chinese Stocks, CYD, SEC Original|Tags: , , , , , |0 Comments

CYD [CHINA YUCHAI INTERNATIONAL] 20-F: CHINA YUCHAI INTERNATIONAL LIMITED Page Certain Definitions and

[CHINA YUCHAI INTERNATIONAL LIMITED Page Certain Definitions and Supplemental Information 2 2 Part I Item 1. Identity of Directors, Senior Management and Advisers 4 Item 2. Offer Statistics and Expected Timetable 4 Item 3. Key Information 4 Item 4. Information on the Company 22 Item 4A. Unresolved Staff Comments 38 Item 5. Operating and Financial Review and Prospects 38 Item] [The particulars of the Company’s subsidiaries as at December 31, 2014 are set forth below: Attributable equity interests Name of company Jurisdiction Direct Indirect Guangxi Yuchai Machinery Company Limited People’s Republic of — 76.4 % Guangxi Yuchai Accessories Manufacturing Company Limited PRC — 76.4 % Guangxi Yulin Yuchai Accessories Manufacturing Company Limited PRC — 74.2 % Guangxi Yuchai Machinery Monopoly] [TO SECTION 302 OF THE SARBANES-OXLEY ACT I, Hoh Weng Ming, certify that: 1. I have reviewed this annual report on Form 20-F of China Yuchai International Limited (the “Company”); 2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements] [TO SECTION 906 OF THE SARBANES-OXLEY ACT (ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. TO SECTION 906 OF THE SARBANES-OXLEY ACT (ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.] [Consent of Independent Registered Public Accountant Firm We consent to the incorporation by reference in the Registration Statement (Form S-8 No. 333-197287) pertaining to the Equity Incentive Plan of China Yuchai International Limited of our reports dated April 15, 2015, with respect to the consolidated financial statements of China Yuchai International Limited and the effectiveness of internal control over financial]

By | 2016-03-28T12:30:47+00:00 April 15th, 2015|Categories: Chinese Stocks, CYD, Webplus ver|Tags: , , , , , |0 Comments

HTHT [China Lodging] 6-K: (Original Filing)

[China Lodging Group, Limited (HTHT) Announces Its Preliminary Results for Hotel Operations in the First Quarter of 2015 SHANGHAI, China, April 15, 2015 (GLOBE NEWSWIRE) -- China Lodging Group, Limited (Nasdaq:HTHT) ("China Lodging Group" or the "Company"), a leading and fast-growing multi-brand hotel group in China, today announced its preliminary results for the hotel operations in the first quarter ended] [FORM 6-K China Lodging Group, Limited No. 2266 Hongqiao Road ______________________ China Lodging Group, Limited Qi Ji Chief Executive Officer Description China Lodging Group, Limited Announces Preliminary Hotel Operating Results for First Quarter of 2015 6-K 1 document.htm FORM 6-K FILING DOCUMENT]

By | 2016-03-28T14:33:48+00:00 April 15th, 2015|Categories: Chinese Stocks, HTHT, SEC Original|Tags: , , , , , |0 Comments

HTHT [China Lodging] 6-K: China Lodging Group, Limited (HTHT) Announces Its Preliminary

[China Lodging Group, Limited (HTHT) Announces Its Preliminary Results for Hotel Operations in the First Quarter of 2015 SHANGHAI, China, April 15, 2015 (GLOBE NEWSWIRE) -- China Lodging Group, Limited (Nasdaq:HTHT) ("China Lodging Group" or the "Company"), a leading and fast-growing multi-brand hotel group in China, today announced its preliminary results for the hotel operations in the first quarter ended] [FORM 6-K China Lodging Group, Limited No. 2266 Hongqiao Road ______________________ China Lodging Group, Limited Qi Ji Chief Executive Officer Description China Lodging Group, Limited Announces Preliminary Hotel Operating Results for First Quarter of 2015 6-K 1 document.htm FORM 6-K FILING DOCUMENT]

By | 2016-03-28T14:34:49+00:00 April 15th, 2015|Categories: Chinese Stocks, HTHT, Webplus ver|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals] 8-K: (Original Filing)

[Biostar Pharmaceuticals, Inc. Announces Its Full Year and Fourth Quarter 2014 Financial Results Full Year 2014 Financial Highlights · Net sales increased by $8.7 million, or 16.5%, year over year, from $52.7 million in 2013 to $61.4 million in 2014. · Gross profit grew by approximately 17.9% from $25.7 million in 2013 to $30.3 million in 2014. · Cash and] [FORM 8-K CURRENT REPORT Date of Report (Date of earliest event reported): April 15, 2015 BIOSTAR PHARMACEUTICALS, INC. Maryland 001-34708 20-8747899 (State or Other Jurisdiction (Commission (I.R.S. Employer of Incorporation) Identification No.) No. 588 Shiji Avenue, Xianyang City, Shaanxi Province, People’s Republic of China 712046 86-029-33686638 N/A (Former name or former address, if changed since last report) ¨ ¨ ¨]

By | 2016-03-28T18:02:25+00:00 April 15th, 2015|Categories: BSPM, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals] 8-K: Biostar Pharmaceuticals, Inc. Announces Its Full Year and

[Biostar Pharmaceuticals, Inc. Announces Its Full Year and Fourth Quarter 2014 Financial Results Full Year 2014 Financial Highlights · Net sales increased by $8.7 million, or 16.5%, year over year, from $52.7 million in 2013 to $61.4 million in 2014. · Gross profit grew by approximately 17.9% from $25.7 million in 2013 to $30.3 million in 2014. · Cash and] [FORM 8-K CURRENT REPORT Date of Report (Date of earliest event reported): April 15, 2015 BIOSTAR PHARMACEUTICALS, INC. Maryland 001-34708 20-8747899 (State or Other Jurisdiction (Commission (I.R.S. Employer of Incorporation) Identification No.) No. 588 Shiji Avenue, Xianyang City, Shaanxi Province, People’s Republic of China 712046 86-029-33686638 N/A (Former name or former address, if changed since last report) ¨ ¨ ¨]

By | 2016-03-28T18:03:29+00:00 April 15th, 2015|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals] 10-K: (Original Filing)

[FORM 10-K (Mark One) x December 31, 2014 For the fiscal year ended: Or ¨ For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, INC. Maryland 20-8747899 (State or other jurisdiction of incorporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province People’s Republic of China 712046 (Zip code) 86-29-33686638 (Former name, former] [Biostar Pharmaceuticals, Inc. List of subsidiaries As of December 31, 2014 Name Place of incorporation Shaanxi Biostar Biotech Ltd People’s Republic of China Shaanxi Aoxing Pharmaceutical Co. Ltd. People’s Republic of China Shaanxi Weinan Haren Pharmaceuticals, Ltd. People’s Republic of China EX-21 2 ex21.htm EX-21] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Board of Directors of Biostar Pharmaceuticals, Inc. Clement C. W. Chan & Co. Certified Public Accountants Hong Kong April 15, 2015 EX-23.1 3 ex23-1.htm EX-23.1] [Consent of Independent Registered Public Accounting Firm To the Board of Directors of Biostar Pharmaceuticals, Inc. Clement C. W. Chan & Co. Certified Public Accountants Hong Kong April 15, 2015 EX-23.2 4 ex23-2.htm EX-23.2] [Consent of Independent Registered Public Accounting Firm To the Board of Directors of Biostar Pharmaceuticals, Inc. Mazars CPA Limited Certified Public Accountants Hong Kong April 15, 2015 EX-23.3 5 ex23-3.htm EX-23.3] [Consent of Independent Registered Public Accounting Firm To the Board of Directors of Biostar Pharmaceuticals, Inc. Mazars CPA Limited Certified Public Accountants Hong Kong April 15, 2015 EX-23.4 6 ex23-4.htm EX-23.4] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this Annual 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period] [CERTIFICATION I, Qinghua Liu, certify that: 1. I have reviewed this Annual 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Dated: April 15, 2015 Ronghua Wang Chief Executive Officer EX-32.1 9 ex32-1.htm EX-32.1] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Dated: April 15, 2015 Qinghua Liu Interim Chief Financial Officer EX-32.2 10 ex32-2.htm EX-32.2]

By | 2016-03-28T18:06:05+00:00 April 15th, 2015|Categories: BSPM, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments
Skip to toolbar